About DayOne and the DayOne Tech accelerator
Located in the Jura (30 minutes from Basel), DayOne Tech is a rapidly growing program for ambitious ventures.
DayOne Tech brings together a community of industry professionals, corporates, universities, hospitals, production partners as well as regulatory and IP experts to reshape the healthcare system.
It’s driven by the philosophy that each startup needs a highly personalized environment to grow and close the gaps between idea and market access. This process involves prototyping, raising funds and scaling up.
But there is one more advantage no other accelerator can offer: the place!
Jura, the Swiss valley of watch manufacturers, is a hot spot for medtech startups in Europe. It’s a perfect collaborative ecosystem of universities, corporations, manufacturers, startup founders, research institutes and hospitals to nurture innovation.
Watch the aftermovie from this year’s DayOne Tech kickoff below.
DayOne Tech startups with revolutionary ideas and solid business strategies
We are proud to present this year’s winners – four medtech startups on the cutting edge of healthcare, providing innovative solutions to address today’s most urgent challenges in disease prevention and treatment.
Xana is on a mission to transform the treatment of neurological diseases. Their approach is a non-invasive customized left auricular vagus nerve stimulation device. By avoiding invasive methods and customizing treatment, Xana aims to reduce the need for pharmacological agents and enhance existing treatment pathways for five different pathologies. It’s a potential game-changer in the field of neurological healthcare.
AiMorphous Health is championing an AI-blood test diagnostic device that focuses on blood clots and bleeding prevention. The potential impact of their innovation is profound, as blood clots and bleeding are critical issues in healthcare. AiMorphous Health’s technology emphasizes early prevention and intervention to reduce thrombosis – a major cause of death globally.
OncoSwab is dedicated to the early detection of lung cancer with a non-invasive medical device. Their technology is designed to identify early-stage lung cancer biomarkers in a non-invasive manner. OncoSwab aims to increase the number of patients worldwide with access to testing.
ClotX is a force to be reckoned with in thrombosis treatment. Their product is designed to optimize thrombosis care by removing the thrombus and minimizing peripheral adverse effects during the treatment process. This is a remarkable achievement, as it improves patient care and enhances the overall quality of life for those suffering from thrombosis.
These four ventures are currently being accelerated. Get insights from their process to develop your own venture by joining our newsletter!
Join the accelerator
If you’re a medtech startup with a first MVP or a clear plan to create one, you might be ready to join our next cohort. Sign up for our newsletter to be notified when the 2024 application call opens.
Please don’t hesitate reaching out to email@example.com for further information.